AU2006230602B2 - Amylin and amylin agonists for treating psychiatric diseases and disorders - Google Patents

Amylin and amylin agonists for treating psychiatric diseases and disorders Download PDF

Info

Publication number
AU2006230602B2
AU2006230602B2 AU2006230602A AU2006230602A AU2006230602B2 AU 2006230602 B2 AU2006230602 B2 AU 2006230602B2 AU 2006230602 A AU2006230602 A AU 2006230602A AU 2006230602 A AU2006230602 A AU 2006230602A AU 2006230602 B2 AU2006230602 B2 AU 2006230602B2
Authority
AU
Australia
Prior art keywords
seq
disorder
amylin
xaa
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006230602A
Other languages
English (en)
Other versions
AU2006230602A1 (en
Inventor
Michael Hanley
Kevin D. Laugero
Christine M. Mack
David G. Parkes
Andrew A. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Publication of AU2006230602A1 publication Critical patent/AU2006230602A1/en
Application granted granted Critical
Publication of AU2006230602B2 publication Critical patent/AU2006230602B2/en
Assigned to Amylin Pharmacueticals, LLC, ASTRA ZENECA PHARMACEUTICALS LP reassignment Amylin Pharmacueticals, LLC Request for Assignment Assignors: AMYLIN PHARMACEUTICALS, INC.
Assigned to ASTRA ZENECA PHARMACEUTICALS LP reassignment ASTRA ZENECA PHARMACEUTICALS LP Request for Assignment Assignors: Amylin Pharmacueticals, LLC, ASTRA ZENECA PHARMACEUTICALS LP
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006230602A 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders Ceased AU2006230602B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US66733505P 2005-03-31 2005-03-31
US66668105P 2005-03-31 2005-03-31
US60/666,681 2005-03-31
US60/667,335 2005-03-31
US67544105P 2005-04-28 2005-04-28
US60/675,441 2005-04-28
US76058306P 2006-01-20 2006-01-20
US60/760,583 2006-01-20
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (2)

Publication Number Publication Date
AU2006230602A1 AU2006230602A1 (en) 2006-10-05
AU2006230602B2 true AU2006230602B2 (en) 2010-07-15

Family

ID=37054153

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006230602A Ceased AU2006230602B2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders
AU2006230420A Ceased AU2006230420B2 (en) 2005-03-31 2006-03-31 Compositions and methods for the control, prevention, and treatment of obesity and eating disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2006230420A Ceased AU2006230420B2 (en) 2005-03-31 2006-03-31 Compositions and methods for the control, prevention, and treatment of obesity and eating disorders

Country Status (17)

Country Link
US (7) US7879794B2 (enExample)
EP (5) EP1888094B1 (enExample)
JP (2) JP5114381B2 (enExample)
KR (3) KR20130122983A (enExample)
CN (3) CN101189021B (enExample)
AT (2) ATE480255T1 (enExample)
AU (2) AU2006230602B2 (enExample)
BR (2) BRPI0606466A2 (enExample)
CA (2) CA2602584A1 (enExample)
DE (2) DE602006008456D1 (enExample)
DK (1) DK1888094T3 (enExample)
EA (1) EA013121B1 (enExample)
ES (1) ES2330671T3 (enExample)
IL (1) IL186200A (enExample)
MX (2) MX2007012237A (enExample)
NZ (3) NZ561936A (enExample)
WO (2) WO2006105345A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2008500281A (ja) * 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0606466A2 (pt) 2005-03-31 2009-06-30 Amylin Pharmaceuticals Inc amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
WO2007104789A2 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
MX2008012666A (es) * 2006-03-31 2008-10-13 Amylin Pharmaceuticals Inc Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP2011525895A (ja) * 2008-06-25 2011-09-29 ノボ・ノルデイスク・エー／エス アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
ES2620610T3 (es) 2008-12-10 2017-06-29 Glaxosmithkline Llc Composiciones farmacéuticas de albiglutide
AU2010206614B2 (en) * 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
EP2416797A4 (en) * 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE
JP2012524125A (ja) 2009-04-20 2012-10-11 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
HRP20171801T1 (hr) 2009-09-28 2017-12-29 Intarcia Therapeutics, Inc. Brzo uspostavljanje i/ili brzo završavanje uglavnom stabilne primjene lijeka
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8691763B2 (en) 2010-05-04 2014-04-08 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
CN102439900A (zh) 2010-06-28 2012-05-02 中兴通讯股份有限公司 一种全封闭式综合接入系统及其降功耗的方法
SG189444A1 (en) 2010-10-19 2013-05-31 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
HRP20201731T1 (hr) 2011-01-07 2020-12-25 Anji Pharma (Us) Llc Terapije na bazi liganda kemozensoričkog receptora
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
UA125895C2 (uk) * 2011-06-17 2022-07-06 Ханмі Сайенс Ко., Лтд. КОН'ЮГАТ, ЩО МІСТИТЬ ПОХІДНУ ОКСИНТОМОДУЛІНУ ТА Fc-ДІЛЯНКУ ІМУНОГЛОБУЛІНУ, ТА ЙОГО ЗАСТОСУВАННЯ
KR20230095124A (ko) 2012-01-06 2023-06-28 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
WO2015017455A1 (en) 2013-07-30 2015-02-05 Soares Christopher J Cgrp agonist peptides
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3506925B1 (en) 2016-09-02 2023-09-06 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
EP3628233B1 (en) * 2018-09-28 2021-06-02 Siemens Healthcare GmbH Method and system for providing a dose reference value for a patient
US11443843B2 (en) 2019-01-04 2022-09-13 International Business Machines Corporation Personal customized guidance for treating patients
AU2020223284A1 (en) 2019-02-17 2021-09-16 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
CN111700904A (zh) * 2020-07-31 2020-09-25 江南大学 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法
EP4366755A4 (en) * 2021-07-08 2025-09-24 Gila Therapeutics Inc COMPOSITIONS AND METHODS FOR ACTIVATING A NEURAL RECEPTOR
TW202530247A (zh) * 2023-12-04 2025-08-01 丹麥商西蘭製藥公司 方法
TW202528338A (zh) * 2023-12-04 2025-07-16 丹麥商西蘭製藥公司 方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065460D1 (en) 1979-07-28 1983-12-08 Beecham Group Plc Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them
US4397780A (en) 1982-02-12 1983-08-09 Armour Pharmaceutical Company Leucine22 -calcitonin
US4401593A (en) 1982-02-12 1983-08-30 Armour Pharmaceutical Company Glycine - 8 calcitonin
US4414149A (en) 1983-03-04 1983-11-08 Armour Pharmaceutical Company Glycine8 -D-arginine24 calcitonin
US4495097A (en) 1983-04-04 1985-01-22 Armour Pharmaceutical Company Des-serine2 -glycine8 calcitonin
US4497731A (en) 1983-04-04 1985-02-05 Armour Pharmaceutical Company Glycine 8-des-tyrosine 22 calcitonin
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
US4597900A (en) 1983-08-22 1986-07-01 Armour Pharmaceutical Co. Des2 -glycine8 -des22 -calcitonin
US4537716A (en) 1983-12-05 1985-08-27 Armour Pharmaceutical Co. Des-serine2 or des-glycine2 -leucine22 calcitonin
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4604238A (en) 1984-12-10 1986-08-05 Armour Pharmaceutical Company Analogs of calcitonin
US4606856A (en) 1985-03-18 1986-08-19 Seyler Jay K [Des-1-amino, 8-glycine]calcitonin
US4652627A (en) 1985-08-16 1987-03-24 Kempe Tomas G Calcitonin analogs with C-terminal D-amino acid substituents
US4687839A (en) 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents
US4697002A (en) 1985-12-23 1987-09-29 Kempe Tomas G Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36
GB8709871D0 (en) 1987-04-27 1987-06-03 Turner R C Peptides
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5405831A (en) 1989-07-08 1995-04-11 Amylin Pharmaceuticals, Inc. Treatment of bone disorders
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
MD960317A (ro) 1991-11-19 1998-05-31 Anylin Pharmaceuticals, Inc. Noile peptide-agoniste ale amilinei şi utilizarea lor
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6001364A (en) 1993-05-05 1999-12-14 Gryphon Sciences Hetero-polyoxime compounds and their preparation by parallel assembly
US5589356A (en) 1993-06-21 1996-12-31 Vanderbilt University Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement
DK0717635T3 (da) 1993-09-07 2000-12-11 Amylin Pharmaceuticals Inc Fremgangsmåder til reduktion af gastrointestinal motilitet
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US6307018B1 (en) 1996-12-24 2001-10-23 The Scripps Research Institute General chemical ligation
CA2277112C (en) * 1997-01-07 2008-08-26 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US20040022807A1 (en) 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
WO1998056807A1 (en) 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
DE69942453D1 (de) 1998-05-29 2010-07-15 Jgc Catalysts & Chemicals Ltd Verfahren zur herstellung photoelektrischer zellen
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
DE69932249T2 (de) 1998-08-31 2007-07-26 Amylin Pharmaceuticals, Inc. (n.d.Ges.d. Staates Delaware), San Diego Chemische anknüpfung unter einbeziehung von einer lipid-matrix und herstellung von membranpolypeptiden
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
MXPA03001469A (es) 2000-09-08 2004-12-13 Gryphon Therapeutics Inc Proteinas sinteticas estimulantes de la eritropoyesis.
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
US20040138412A1 (en) 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
WO2003042235A2 (en) 2001-11-14 2003-05-22 Geneprot, Inc. Extended native chemical ligation of three or more peptide fragments
ES2316757T3 (es) 2002-01-08 2009-04-16 Amylin Pharmaceuticals, Inc. Uso de agonistas de amilina para modular trigliceridos.
MY133587A (en) * 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
WO2004007661A2 (en) 2002-06-10 2004-01-22 Geneprot, Inc. Carboxy protection strategies for acidic c-terminal amino acids in chemical ligation of oligopeptides
US6965013B2 (en) 2002-11-26 2005-11-15 The Board Of Trustees Of The Leland Stanford Junior University Intermedin and its uses
WO2004060925A2 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Multiplex polymer ligation
US20040197287A1 (en) * 2003-04-04 2004-10-07 The Procter & Gamble Company Personal care composition containing an antidandruff component and a nonionic surfactant
EP1631597A4 (en) 2003-05-22 2007-07-11 Gryphon Therapeutics Inc SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
WO2006042242A2 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them
BRPI0606466A2 (pt) 2005-03-31 2009-06-30 Amylin Pharmaceuticals Inc amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos

Also Published As

Publication number Publication date
DK1888094T3 (da) 2009-11-09
MX2007012236A (es) 2007-12-06
NZ578299A (en) 2010-03-26
KR101383493B1 (ko) 2014-04-11
AU2006230420A1 (en) 2006-10-05
EP2258382A2 (en) 2010-12-08
EA013121B1 (ru) 2010-02-26
EP1888094A2 (en) 2008-02-20
EP2248527A2 (en) 2010-11-10
IL186200A0 (en) 2008-01-20
US20100125054A1 (en) 2010-05-20
CN101189021A (zh) 2008-05-28
US7879794B2 (en) 2011-02-01
US8278267B2 (en) 2012-10-02
US20090062193A1 (en) 2009-03-05
AU2006230420B2 (en) 2011-11-24
US20130225485A1 (en) 2013-08-29
JP5114381B2 (ja) 2013-01-09
CA2602584A1 (en) 2006-10-05
US20110288028A1 (en) 2011-11-24
JP2008534627A (ja) 2008-08-28
WO2006105345A9 (en) 2007-03-22
US7671023B2 (en) 2010-03-02
CA2602261A1 (en) 2006-10-05
IL186200A (en) 2013-09-30
KR20080003849A (ko) 2008-01-08
BRPI0609595A2 (pt) 2010-04-20
WO2006105527A2 (en) 2006-10-05
US20110263491A1 (en) 2011-10-27
ATE480255T1 (de) 2010-09-15
WO2006105527A3 (en) 2007-01-11
MX2007012237A (es) 2007-12-07
DE602006016760D1 (de) 2010-10-21
EP2248527A3 (en) 2013-04-03
BRPI0606466A2 (pt) 2009-06-30
ATE439140T1 (de) 2009-08-15
US20130184213A1 (en) 2013-07-18
EP1871403B1 (en) 2010-09-08
DE602006008456D1 (de) 2009-09-24
EP1888094B1 (en) 2009-08-12
CN102343084A (zh) 2012-02-08
WO2006105345A3 (en) 2007-02-01
KR20070119718A (ko) 2007-12-20
NZ561936A (en) 2009-07-31
EP2135617A3 (en) 2013-09-18
KR20130122983A (ko) 2013-11-11
US8389477B2 (en) 2013-03-05
JP2008534606A (ja) 2008-08-28
EP2258382A3 (en) 2014-05-14
CN101189021B (zh) 2011-12-14
ES2330671T3 (es) 2009-12-14
BRPI0609595A8 (pt) 2018-05-15
EA200702126A1 (ru) 2008-04-28
US20080287355A1 (en) 2008-11-20
JP5415067B2 (ja) 2014-02-12
EP1871403A2 (en) 2008-01-02
AU2006230602A1 (en) 2006-10-05
NZ578298A (en) 2010-07-30
EP2135617A2 (en) 2009-12-23
WO2006105345A2 (en) 2006-10-05
CN101415435A (zh) 2009-04-22

Similar Documents

Publication Publication Date Title
AU2006230602B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
US7399744B2 (en) Methods for affecting body composition
KR101123549B1 (ko) 비만 및 관련 장애의 치료
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
US20130035294A1 (en) Neuromedin and FN-38 Peptides for Psychotic Diseases
US20070275877A1 (en) Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
CN101208098A (zh) 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
CA2674186A1 (en) Use of somatostatin analogs in cluster headache

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: AMYLIN PHARMACUETICALS, LLC; ASTRA ZENECA PHARMACE

Free format text: FORMER OWNER WAS: AMYLIN PHARMACEUTICALS, INC.

PC Assignment registered

Owner name: ASTRA ZENECA PHARMACEUTICALS LP

Free format text: FORMER OWNER WAS: ASTRA ZENECA PHARMACEUTICALS LP; AMYLIN PHARMACUETICALS, LLC

TH Corrigenda

Free format text: IN VOL 27 , NO 5 , PAGE(S) 808 UNDER THE HEADING ASSIGNMENTS REGISTERED UNDER THE NAME ASTRA ZENECAPHARMACEUTICALS LP, APPLICATION NO. 2006230602, UNDER INID (71), CORRECT THE NAME TO ASTRAZENECA PHARMACEUTICALS AND AMYLIN PHARMACEUTICALS, LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired